NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

BACKGROUND: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. Ho...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Enjoji, Munechika, Machida, Kazuyuki, Kohjima, Motoyuki, Kato, Masaki, Kotoh, Kazuhiro, Matsunaga, Kazuhisa, Nakashima, Manabu, Nakamuta, Makoto
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2010
Témata:
Short Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2847569/
https://ncbi.nlm.nih.gov/pubmed/20222991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-511X-9-29
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky